M J Brennan

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Propelling novel vaccines directed against tuberculosis through the regulatory process
    M J Brennan
    Laboratory of Mycobacteria, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852 1448, USA
    Tuber Lung Dis 79:145-51. 1999
  2. ncbi request reprint Moving new vaccines for tuberculosis through the regulatory process
    M J Brennan
    Laboratory of Mycobacteria, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Infect Dis 30:S247-9. 2000
  3. pmc Evidence that mycobacterial PE_PGRS proteins are cell surface constituents that influence interactions with other cells
    M J Brennan
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 69:7326-33. 2001
  4. ncbi request reprint Global Forum on TB Vaccine Research and Development. World Health Organization, June 7-8 2001, Geneva
    M J Brennan
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Tuberculosis (Edinb) 81:365-8. 2001
  5. ncbi request reprint Tuberculosis vaccine development: research, regulatory and clinical strategies
    Michael J Brennan
    Center for Biologics Evaluation and Research, Laboratory of Mycobacterial Diseases and Cellular Immunology, Food and Drug Administration, Bldg 29 Rm 503 HFM 431, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 4:1493-504. 2004
  6. ncbi request reprint The PE multigene family: a 'molecular mantra' for mycobacteria
    Michael J Brennan
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29 Room 502, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Trends Microbiol 10:246-9. 2002
  7. ncbi request reprint The tuberculosis vaccine challenge
    Michael J Brennan
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29 Rm 503 HFM 431, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Tuberculosis (Edinb) 85:7-12. 2005
  8. pmc Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis
    G Delogu
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 69:5606-11. 2001
  9. doi request reprint A comparative study of host response to three Mycobacterium tuberculosis PE_PGRS proteins
    Prachi P Singh
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20910, USA
    Microbiology 154:3469-79. 2008
  10. pmc The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis
    Marcela Parra
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29, Rm 503, HFM 431, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Infect Immun 72:6799-805. 2004

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Propelling novel vaccines directed against tuberculosis through the regulatory process
    M J Brennan
    Laboratory of Mycobacteria, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852 1448, USA
    Tuber Lung Dis 79:145-51. 1999
    ..It is hoped that the comments provided here will help accelerate the development of new effective vaccines for the prevention and treatment of tuberculosis...
  2. ncbi request reprint Moving new vaccines for tuberculosis through the regulatory process
    M J Brennan
    Laboratory of Mycobacteria, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Infect Dis 30:S247-9. 2000
    ....
  3. pmc Evidence that mycobacterial PE_PGRS proteins are cell surface constituents that influence interactions with other cells
    M J Brennan
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 69:7326-33. 2001
    ..Together these results suggest that certain PE_PGRS proteins may be found at the surface of mycobacteria and influence both cell surface interactions among mycobacteria as well as the interactions of mycobacteria with macrophages...
  4. ncbi request reprint Global Forum on TB Vaccine Research and Development. World Health Organization, June 7-8 2001, Geneva
    M J Brennan
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Tuberculosis (Edinb) 81:365-8. 2001
    ....
  5. ncbi request reprint Tuberculosis vaccine development: research, regulatory and clinical strategies
    Michael J Brennan
    Center for Biologics Evaluation and Research, Laboratory of Mycobacterial Diseases and Cellular Immunology, Food and Drug Administration, Bldg 29 Rm 503 HFM 431, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 4:1493-504. 2004
    ....
  6. ncbi request reprint The PE multigene family: a 'molecular mantra' for mycobacteria
    Michael J Brennan
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29 Room 502, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Trends Microbiol 10:246-9. 2002
    ....
  7. ncbi request reprint The tuberculosis vaccine challenge
    Michael J Brennan
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29 Rm 503 HFM 431, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Tuberculosis (Edinb) 85:7-12. 2005
    ..This presents a major challenge to pre-clinical testing and clinical evaluation as well as eventual uptake of the new TB vaccines into areas of the world that are most at risk for tuberculosis...
  8. pmc Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis
    G Delogu
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 69:5606-11. 2001
    ..These results suggest that the PE vaccine can elicit an effective cellular immune response and that immune recognition of the PE antigen is influenced by the Gly-Ala-rich PGRS domain...
  9. doi request reprint A comparative study of host response to three Mycobacterium tuberculosis PE_PGRS proteins
    Prachi P Singh
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20910, USA
    Microbiology 154:3469-79. 2008
    ..tuberculosis...
  10. pmc The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis
    Marcela Parra
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29, Rm 503, HFM 431, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Infect Immun 72:6799-805. 2004
    ..tuberculosis are critical for generating effective host immune responses. The vaccine studies described here demonstrate that HBHA is a promising new vaccine candidate for tuberculosis...
  11. pmc A PE protein expressed by Mycobacterium avium is an effective T-cell immunogen
    Marcela Parra
    Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29, Rm 503, HFM 431, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Infect Immun 74:786-9. 2006
    ..Immunization with an MaPE DNA vaccine protected mice against an aerosol challenge with Mycobacterium tuberculosis, suggesting that mycobacteria express PE antigens with cross-protective T-cell epitopes...
  12. doi request reprint A rational vaccine pipeline for tuberculosis
    M J Brennan
    Global Affairs, Aeras, Rockville, Maryland 20850, USA
    Int J Tuberc Lung Dis 16:1566-73. 2012
    ..This will require TB vaccines that are both safe and effective in all populations. It cannot be accomplished without hard work as well as additional resources that match the ambitious goals of the TB community...
  13. pmc Variable expression patterns of Mycobacterium tuberculosis PE_PGRS genes: evidence that PE_PGRS16 and PE_PGRS26 are inversely regulated in vivo
    Veerabadran Dheenadhayalan
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Bacteriol 188:3721-5. 2006
    ..tuberculosis. Variable expression of PE_PGRS proteins could have implications for their role in the immunopathogenesis of tuberculosis...
  14. ncbi request reprint Expression of the PE_PGRS 33 protein in Mycobacterium smegmatis triggers necrosis in macrophages and enhanced mycobacterial survival
    Veerabadran Dheenadhayalan
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29, Room 503, HFM 431, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Microbes Infect 8:262-72. 2006
    ....
  15. ncbi request reprint Peptide nucleic acid probe detection of mutations in Mycobacterium tuberculosis genes associated with drug resistance
    L E Bockstahler
    US Food and Drug Administration, Rockville, MD 20857, USA
    Biotechniques 32:508-10, 512, 514. 2002
    ..Using the M. tuberculosis cloned genes and PCR-PNA-ELISA format developed here, M. tuberculosis sequences containing point mutations associated with drug resistance can be identified in less than 24 h...
  16. doi request reprint Tuberculosis vaccine research: the impact of immunology
    Lewellys F Barker
    Aeras Global TB Vaccine Foundation, Rockville, MD 20850, USA
    Curr Opin Immunol 21:331-8. 2009
    ....
  17. pmc Development of new tuberculosis vaccines: a global perspective on regulatory issues
    Michael J Brennan
    Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland, United States of America
    PLoS Med 4:e252. 2007
  18. ncbi request reprint Cloning and sequencing of the structural gene for the porin protein of Bordetella pertussis
    Z M Li
    Division of Bacterial Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland 20892
    Mol Microbiol 5:1649-56. 1991
    ..DNA hybridization studies indicated that both virulent and avirulent strains of B. pertussis contain only one copy of this gene and that Bordetella bronchiseptica and Bordetella parapertussis contain a similar gene...
  19. ncbi request reprint Rv1818c-encoded PE_PGRS protein of Mycobacterium tuberculosis is surface exposed and influences bacterial cell structure
    Giovanni Delogu
    Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43 B, 07100 Sassari, Italy
    Mol Microbiol 52:725-33. 2004
    ..Regulated expression of PE genes could have implications for the survival and pathogenesis of mycobacteria within the human host and in other environmental niches...
  20. ncbi request reprint PE_PGRS proteins are differentially expressed by Mycobacterium tuberculosis in host tissues
    Giovanni Delogu
    Institute of Microbiology, Catholic University of Sacred Heart, L go A Gemelli, 8, 00168 Rome, Italy
    Microbes Infect 8:2061-7. 2006
    ..The results of this study indicate that M. tuberculosis can differentially regulate expression of PE_PGRS genes and that genes such as rv0746 and rv1651c are significantly induced while M. tuberculosis persists in host cells and tissues...
  21. ncbi request reprint New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development
    Arun T Kamath
    Department of Pathology and Immunology, Center for Vaccinology and Neonatal Immunology, University of Geneva, 1 rue Michel Servet, 1211 Geneva, Switzerland
    Vaccine 23:3753-61. 2005
    ..The proposed criteria suggested in this consensus document may facilitate the movement of the most promising vaccine candidates to the clinic and towards control of tuberculosis...
  22. ncbi request reprint Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin
    Stephane Temmerman
    Laboratory of Immunology, Erasme Hospital, Universite Libre de Bruxelles, Route de Lennik, 808, B 1070 Brussels, Belgium
    Nat Med 10:935-41. 2004
    ..Thus, post-translational modifications of proteins may be crucial for their ability to induce protective T cell-mediated immunity against infectious diseases such as tuberculosis...
  23. ncbi request reprint Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines
    Gerald M Aronoff
    Carolina Pain Associates, Presbyterian Orthopedic Hospital, Charlotte, NC 28207, USA
    Pain Med 6:305-14. 2005
    ..To review the evidence for dosing and efficacy of oral transmucosal fentanyl citrate in the management of pain and produce dosing guidelines...
  24. ncbi request reprint Expression and purification of recombinant methylated HBHA in Mycobacterium smegmatis
    Giovanni Delogu
    Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43 B, 07100 Sassari
    FEMS Microbiol Lett 239:33-9. 2004
    ..The use of fast-growing strains of M. smegmatis to obtain significant amounts of purified HBHA protein within a short timeframe, should be an effective strategy for the evaluation of a new HBHA-based vaccine candidate for tuberculosis...